Guojin Securities: Multi-dimensional catalysts for the MASH sector are materializing rapidly, supporting Madrigal's long-term double-digit growth outlook.

The FDA has accepted the proposal for a non-invasive surrogate endpoint, potentially accelerating the development of new drugs for MASH.

Zhitong FinanceJul 16 13:44

Huadong Medicine's Attributable Profit Jumps 9.6% in H1

MT NewswiresJul 9 12:53

Huadong Medicine: First Quarter 2026 Report (English Version)

SZSIJul 9 00:00 · Announcements

East China Pharmaceutical: 2025 Annual Report (English Version)

SZSIJul 9 00:00 · Announcements

Guotai Haitong: Unlocking Opportunities in the Multi-Billion-Dollar Metabolic and Chronic Disease Sector—Focus on Fibrosis Improvement Endpoints

The bank believes MNC is well positioned to further expand its portfolio around MASH assets and pursue overseas opportunities for assets with differentiated competitive advantages.

Zhitong FinanceJul 7 10:15

Huadong Medicine Gets Clinical Trial Approval for Cancer Drug; Shares Down 3%

MT NewswiresJun 26 12:46